Humacyte, Inc. Insider Trading

HUMA

⊜ Compare

Last 12 months

Insiders bought 90K and sold 83K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+7K

5 buys · 2 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

3 / 2

executives and directors

Last open-market buy

Sep 2026

Sep 14, 2026

Get an email when HUMA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 14	Keith Anthony Jones Director	Bought	10,000	$0.56	6K	25%	Form 4
Aug 20	Keith Anthony Jones Director	Bought	10,000	$0.69	7K	33%	Form 4
Aug 17	Keith Anthony Jones Director	Bought	30,000	$0.59	18K	New	Form 4
May 19	Kathleen Sebelius Director	Bought	56,818	$0.88	50K	62%	Form 4
May 18	Shamik J Parikh Chief Medical Officer	Sold10b5-1 plan	45,887	$0.90	41K	14%	Form 4
May 18	Dale A. Sander CFO and Chief Corp. Dev. Off	Sold10b5-1 plan	45,887	$0.90	41K	13%	Form 4
May 18	Michael T. Constantino Director	Bought	11,000	$0.89	10K	33%	Form 4
Aug 18, 2025 – Aug 20, 2025	Brady W Dougan Director	SoldNo plan 3 parts	2,241,045	$1.67 average	$3.73M	62%	Form 4
Aug 18, 2025 – Aug 20, 2025	Laura E Niklason President, CEO and Director	SoldNo plan 3 parts	2,241,045	$1.67 average	$3.73M	62%	Form 4
Apr 14, 2025	William John Scheessele Chief Commercial Officer	Bought	6,493	$1.54	10K	42%	Form 4
Apr 10, 2025	Dale A. Sander CFO and Chief Corp. Deve. Off.	Bought	20,000	$1.53	31K	88%	Form 4
Apr 10, 2025	Shamik J Parikh Chief Medical Officer	Bought	7,500	$1.55	12K	New	Form 4
Apr 8, 2025	Kathleen Sebelius Director	Bought	50,000	$1.32	66K	121%	Form 4
Apr 8, 2025	Charles Bruce Green Director	Bought	6,000	$1.29	8K	250%	Form 4
Apr 7, 2025	Michael T. Constantino Director	Bought	16,000	$1.26	20K	94%	Form 4
Dec 4, 2024	Michael T. Constantino Director	Bought	4,600	$4.39	20K	37%	Form 4
Nov 18, 2024 – Nov 20, 2024	Laura E Niklason President, CEO and Director	SoldNo plan 3 parts	1,500,000	$4.40 average	$6.61M	29%	Form 4
Nov 18, 2024 – Nov 20, 2024	Brady W Dougan Director	SoldNo plan 3 parts	1,500,000	$4.40 average	$6.61M	29%	Form 4
Nov 19, 2024	Laura E Niklason President, CEO and Director	Bought	1,797	$4.44	8K	<0.1%	Form 4
Nov 19, 2024	Brady W Dougan Director	Bought	1,797	$4.44	8K	<0.1%	Form 4

Sep 14
Keith Anthony Jones
Director · bought 10,000 at $0.56
6K
25% of stake
Aug 20
Keith Anthony Jones
Director · bought 10,000 at $0.69
7K
33% of stake
Aug 17
Keith Anthony Jones
Director · bought 30,000 at $0.59
18K
New position
May 19
Kathleen Sebelius
Director · bought 56,818 at $0.88
50K
62% of stake
May 1810b5-1 plan
Shamik J Parikh
Chief Medical Officer · sold 45,887 at $0.90
41K
14% of stake
May 1810b5-1 plan
Dale A. Sander
CFO and Chief Corp. Dev. Off · sold 45,887 at $0.90
41K
13% of stake
May 18
Michael T. Constantino
Director · bought 11,000 at $0.89
10K
33% of stake
Aug 18, 2025 – Aug 20, 2025No plan
Brady W Dougan
Director · sold 2,241,045 at avg $1.67
$3.73M
62% of stake
Aug 18, 2025 – Aug 20, 2025No plan
Laura E Niklason
President, CEO and Director · sold 2,241,045 at avg $1.67
$3.73M
62% of stake
Apr 14, 2025
William John Scheessele
Chief Commercial Officer · bought 6,493 at $1.54
10K
42% of stake
Apr 10, 2025
Dale A. Sander
CFO and Chief Corp. Deve. Off. · bought 20,000 at $1.53
31K
88% of stake
Apr 10, 2025
Shamik J Parikh
Chief Medical Officer · bought 7,500 at $1.55
12K
New position
Apr 8, 2025
Kathleen Sebelius
Director · bought 50,000 at $1.32
66K
121% of stake
Apr 8, 2025
Charles Bruce Green
Director · bought 6,000 at $1.29
8K
250% of stake
Apr 7, 2025
Michael T. Constantino
Director · bought 16,000 at $1.26
20K
94% of stake
Dec 4, 2024
Michael T. Constantino
Director · bought 4,600 at $4.39
20K
37% of stake
Nov 18, 2024 – Nov 20, 2024No plan
Laura E Niklason
President, CEO and Director · sold 1,500,000 at avg $4.40
$6.61M
29% of stake
Nov 18, 2024 – Nov 20, 2024No plan
Brady W Dougan
Director · sold 1,500,000 at avg $4.40
$6.61M
29% of stake
Nov 19, 2024
Laura E Niklason
President, CEO and Director · bought 1,797 at $4.44
8K
<0.1% of stake
Nov 19, 2024
Brady W Dougan
Director · bought 1,797 at $4.44
8K
<0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch HUMA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with HUMA

CompareIntrinsic value

OTLKOutlook Therapeutics Inc.

$0.46+0.46%10

SCNIScinai Immunotherapeutics Ltd.

$0.45-4.92%30

INBXInhibrx Biosciences, Inc.

$86.76+7.01%15

PLURPluri Inc.

$1.23-3.15%30

PROKProKidney Corp

$1.12+4.67%10

IMAImageneBio, Inc.

$4.10+1.99%10

CRDFCardiff Oncology Inc.

$0.87+1.03%36

ALGSAligos Therapeutics Inc.

$5.02+5.68%10

Held by ETFs

HUMA is in 4 US ETFs. The largest of them, with HUMA's weight in each:

Spot a number that looks wrong? Check it in HUMA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HUMA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.